Schistosomiasis is blood-dwelling parasites of the genus Schistosoma, mainly S. mansoni, S. japonicum and S. haematobium. Praziquantel® (PZQ) is the drug of choice for treatment but, its efficacy decreased as drug resistant strains emerged due to widespread usages. This study assessed the in-vivo anti-schistosomal effects of Tamoxifen® (TAM) compared to praziquantel on experimental S. mansoni-infected mice regarding worm burden, liver enzymes status, cytokines change, histopathological study and the activities of some antioxidants. Mice were infected by ~80±10 cercariae followed by a single oral dose with either praziquantel or tamoxifen 42 days post-infection. The treated mice showed a reduction in worm burden, a decrease in egg load in liver and intestine, a decrease in levels of AST, ALT, interferon-gamma, interleukin 4, and interleukin 10 but, with a significant activities increase of superoxide dismutase (SOD), glutathiones- transferase (GST), glutathione peroxidase (GPx) and Catalase (CAT) and decrease in granuloma size than infected non-treated mice
HAFEZ, A., MOHAMED, A., & SHAKRA, M. (2023). TAMOXIFEN VERSUS PRAZIQUANTEL IN TREATING SCHISTOSOMIASIS MANSONI IN EXPERIMENTAL INFECTED ALBINO MICE. Journal of the Egyptian Society of Parasitology, 53(2), 211-218. doi: 10.21608/jesp.2023.312097
MLA
ADEL OMAR HAFEZ; AHMED M. A. MOHAMED; MOHAMMED YOUSSEF SHAKRA. "TAMOXIFEN VERSUS PRAZIQUANTEL IN TREATING SCHISTOSOMIASIS MANSONI IN EXPERIMENTAL INFECTED ALBINO MICE". Journal of the Egyptian Society of Parasitology, 53, 2, 2023, 211-218. doi: 10.21608/jesp.2023.312097
HARVARD
HAFEZ, A., MOHAMED, A., SHAKRA, M. (2023). 'TAMOXIFEN VERSUS PRAZIQUANTEL IN TREATING SCHISTOSOMIASIS MANSONI IN EXPERIMENTAL INFECTED ALBINO MICE', Journal of the Egyptian Society of Parasitology, 53(2), pp. 211-218. doi: 10.21608/jesp.2023.312097
VANCOUVER
HAFEZ, A., MOHAMED, A., SHAKRA, M. TAMOXIFEN VERSUS PRAZIQUANTEL IN TREATING SCHISTOSOMIASIS MANSONI IN EXPERIMENTAL INFECTED ALBINO MICE. Journal of the Egyptian Society of Parasitology, 2023; 53(2): 211-218. doi: 10.21608/jesp.2023.312097